Where untapped medical potential and private equity intersect
Princeton Biopharma Capital Partners, LLC, is a private-equity investment firm focused on investing in commercial-stage healthcare companies.
We provide financial and intellectual capital to commercial-stage healthcare companies with products with growth potential that make a significant impact on patients’ lives.
Latest News
- Kaléo Awarded $96.1 Million BARDA Contract to Advance 2-PAM Auto-Injector for U.S. Chemical Threat PreparednessBase award supports late-stage development, regulatory approval activities, and initial procurement of Kaléo’s next-generation 2-PAM auto-injector… Read more: Kaléo Awarded $96.1 Million BARDA Contract to Advance 2-PAM Auto-Injector for U.S. Chemical Threat Preparedness
- Kaleo’s AUVI-Q® (epinephrine injection, USP) Selected by Axiom Space to Help Protect Crew from Allergic EmergenciesRichmond, Virginia, July 24, 2025 (GLOBE NEWSWIRE) — Kaléo, a global leader in drug-delivery device technology… Read more: Kaleo’s AUVI-Q® (epinephrine injection, USP) Selected by Axiom Space to Help Protect Crew from Allergic Emergencies
- National Organizations Unite to Prepare Early Childcare Facilities for Rising Incidence of Food AllergiesThe Early Childhood Anaphylaxis Collaborative is rallying the nation’s early childcare centers to improve their preparedness… Read more: National Organizations Unite to Prepare Early Childcare Facilities for Rising Incidence of Food Allergies